260. シトステロール血症 [臨床試験数:13,薬物数:13(DrugBank:4),標的遺伝子数:1,標的パスウェイ数:1

Searched query = "Sitosterolemia"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
13 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01948648February 6, 20186/9/2013Effects of Fish Oil and Colesevelam (STAIR7007)Effects of Fish Oil, Colesevelam and Combination Therapy on Sterol Metabolism in SitosterolemiaSitosterolemiaDrug: Colesevelam;Dietary Supplement: Fish Oil;Drug: Combination of fish oil and colesevelamUniversity of ManitobaNULLActive, not recruiting8 YearsN/AAll13N/ACanada
2NCT01584206April 201216/4/2012Sitosterolemia MetabolismAssessment of Sterol Metabolism in Sitosterolemia: A Pilot Study of Patients Treated With EzetimibeSitosterolemiaDrug: EzetimibeUniversity of ManitobaNULLCompleted16 Years99 YearsAll8N/ACanada
3NCT00531128September 10, 200714/9/2007The Effect of Dietary Sitosterol on Blood Sugar and CholesterolA Nutrigenomics Intervention for the Study of the Role of Dietary Sitosterol on Lipid, Glucose and Energy MetabolismSitosterolemiaBehavioral: High/Low SitosterolNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NULLCompleted18 YearsN/AAll14N/AUnited States
4NCT00705211June 200723/6/2008A 52-week Post-marketing, Observational Study to Confirm the Safety and Efficacy of Zetia Alone or in Combination With Other Lipid-lowering Drugs in Japanese Subjects With Hypercholesterolemia (Study P05245)Designated Drug Use Investigation (Long-Term Administration) of Zetia 10-mg Tablets - A 52-Week Long-Term Designated Drug Use Investigation of Zetia Monotherapy and Combination TherapyHypercholesterolemia;Familial Hypercholesterolemia;Homozygous SitosterolemiaDrug: Ezetimibe;Drug: Ezetimibe + other lipid-lowering medication(s)Merck Sharp & Dohme Corp.BayerCompletedN/AN/ABoth1794N/ANULL
5NCT00704444June 200723/6/2008A 12-week Post-marketing, Observational Study to Confirm the Safety and Efficacy of Zetia Alone or in Combination With Other Lipid-lowering Drugs in Japanese Subjects With Hypercholesterolemia (Study P05244)Designated Drug Use Investigation (12 Weeks) of Zetia 10mg Tablets - A 12-Week Designated Drug Use Investigation of Zetia Monotherapy and Combination TherapyHypercholesterolemia;Familial Hypercholesterolemia;Homozygous SitosterolemiaDrug: Ezetimibe;Drug: Ezetimibe + other lipid-lowering medication(s)Merck Sharp & Dohme Corp.BayerCompletedN/AN/ABoth11332N/ANULL
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6EUCTR2004-001580-22-DE21/12/200420/10/2004A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of Adding Ezetimibe 30 mg to an Ongoing Regimen of Ezetimibe 10 mg in Patients With Homozygous Sitosterolemia - Sitosterolemia High Dose StudyA Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of Adding Ezetimibe 30 mg to an Ongoing Regimen of Ezetimibe 10 mg in Patients With Homozygous Sitosterolemia - Sitosterolemia High Dose Study Homozygous SitosterolemiaTrade Name: Ezetrol
Product Name: Ezetrol
Product Code: MK-0653
MSD SHARP & DOHME GMBHNULLNot RecruitingFemale: yes
Male: yes
30Germany;United Kingdom
7EUCTR2004-001580-22-GB16/12/200424/02/2005A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of Adding Ezetimibe 30 mg to an Ongoing Regimen of Ezetimibe 10 mg in Patients With Homozygous Sitosterolemia - Sitosterolemia High Dose StudyA Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of Adding Ezetimibe 30 mg to an Ongoing Regimen of Ezetimibe 10 mg in Patients With Homozygous Sitosterolemia - Sitosterolemia High Dose Study Homozygous SitosterolemiaTrade Name: Ezetrol
Product Name: Ezetrol
Product Code: MK-0653
Merck Sharp & Dohme LtdNULLNot RecruitingFemale: yes
Male: yes
30Germany;United Kingdom
8NCT00099996December 200421/12/2004Higher-Dose Ezetimibe to Treat Homozygous SitosterolemiaA Study to Assess Adding Ezetimibe 30 mg to Ongoing Treatment With Ezetimibe 10 mg in Patients With Homozygous SitosterolemiaHeart Diseases;Metabolism, Inborn ErrorsDrug: SCH-58235;Drug: EzetimibeNational Heart, Lung, and Blood Institute (NHLBI)NULLCompletedN/AN/ABoth3Phase 3United States
9NCT00092898October 200423/9/2004An Investigational Drug Study to Lower Non-Cholesterol Sterol Levels Associated With Sitosterolemia (0653-062)(COMPLETED)A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of Adding Ezetimibe 30 mg to An Ongoing Regimen of Ezetimibe 10 mg in Patients Homozygous SitosterolemiaLipid Metabolism, Inborn Errors;Heart DiseaseDrug: MK0653, ezetimibe;Drug: Comparator: placeboMerck Sharp & Dohme Corp.NULLCompleted18 Years85 YearsAll30Phase 3United States
10NCT00092833July 200223/9/2004Investigational Drug in Patients With Hypercholesterolemia or in Patients With Sitosterolemia (0653-026)(COMPLETED)An Open-Label, Worldwide, Treatment Use Study to Provide Ezetimibe 10 Mg/Day to Patients With Homozygous Familial Hypercholesterolemia or Homozygous SitosterolemiaHypercholesterolemia, Familial;Lipid Metabolism, Inborn ErrorsDrug: Comparator: ezetimibeMerck Sharp & Dohme Corp.NULLTerminated8 YearsN/AAll49Phase 3United States
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
11NCT00045812March 200110/9/2002SCH-58235 (Ezetimibe) to Treat Homozygous SitosterolemiaA Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate SCH-58235 in Homozygous SitosterolemiaLipoidosisDrug: SCH-58235National Heart, Lung, and Blood Institute (NHLBI)NULLCompletedN/AN/ABoth5Phase 2United States
12NCT00092820February 12, 200123/9/2004Sitosterolemia Extension Study (0653-004)(COMPLETED)A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of MK0653 When Added to Current Regimen in Patients With Homozygous SitosterolemiaLipid Metabolism, Inborn Errors;Heart DiseaseDrug: MK0653, ezetimibe;Drug: Comparator: placeboMerck Sharp & Dohme Corp.NULLCompleted10 YearsN/AAll58Phase 3NULL
13NCT00092807February 12, 200123/9/2004Sitosterolemia Extension Study (0653-003)(COMPLETED)A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of MK0653 When Added to Current Regimen in Patients With Homozygous Sitosterolemia - 1 Year Open-Label ExtensionLipid Metabolism, Inborn Errors;Heart DiseaseDrug: MK0653, ezetimibe;Drug: Comparator: placeboMerck Sharp & Dohme Corp.NULLCompleted10 YearsN/AAll37Phase 3United States